Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
24/09/2026 20:21
BRIEF-FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component Sept 24 (Reuters) - FDA:
FDA APPROVES BELZUTIFAN IN COMBINATION WITH LENVATINIB FOR ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT
FDA: RECOMMENDED DOSAGE IS 20 MG OF LENVATINIB IN COMBINATION WITH 120 MG OF BELZUTIFAN ONCE DAILY UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY
Further company coverage: MRK.N
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines